Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Retained Earnings (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Retained Earnings for 15 consecutive years, with -$183.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 0.86% to -$183.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$183.8 million, a 0.86% decrease, with the full-year FY2024 number at -$183.5 million, down 4.92% from a year prior.
  • Retained Earnings was -$183.8 million for Q3 2025 at NovaBay Pharmaceuticals, down from -$177.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$137.6 million in Q1 2021 to a low of -$183.8 million in Q3 2025.
  • A 5-year average of -$162.1 million and a median of -$163.9 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: decreased 13.71% in 2023, then rose 1.49% in 2025.
  • NovaBay Pharmaceuticals' Retained Earnings stood at -$141.9 million in 2021, then decreased by 11.46% to -$158.2 million in 2022, then dropped by 10.56% to -$174.8 million in 2023, then dropped by 4.92% to -$183.5 million in 2024, then fell by 0.2% to -$183.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Retained Earnings are -$183.8 million (Q3 2025), -$177.7 million (Q2 2025), and -$175.8 million (Q1 2025).